AI assistant
Moderna, Inc. — Director's Dealing 2024
Feb 29, 2024
30610_dirs_2024-02-29_eef7737a-d10d-4fb1-93c3-a7108051b535.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2024-02-27
Reporting Person: Klinger Shannon Thyme (Chief Legal Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-27 | Stock Option (Right to Buy) | $96.20 | A | 23635 | Acquired | 2034-02-27 | Common Stock (23635) | Direct |
| 2024-02-27 | Restricted Stock Units | $0 | A | 12377 | Acquired | Common Stock (12377) | Direct | |
| 2024-02-27 | Stock Option (Right to Buy) | $96.20 | A | 60216 | Acquired | 2034-02-27 | Common Stock (60216) | Direct |
| 2024-02-27 | Restricted Stock Units | $0 | A | 10609 | Acquired | Common Stock (10609) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 7912 | Direct |
Footnotes
F1: 25% of this option will vest and become exercisable on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F2: 25% of the shares subject to this restricted stock unit award will vest on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F3: 50% of this option will vest and become exercisable on February 27, 2026 and the remaining 50% will vest and become exercisable on February 27, 2027, subject to the recipient's continued service.
F4: 25% of the shares subject to this restricted stock unit award will vest on May 27, 2024 with the remainder vesting in three (3) equal quarterly installments thereafter.